Back to Search
Start Over
New thiazolidine-2,4-diones as effective anti-proliferative and anti-VEGFR-2 agents: Design, synthesis, in vitro, docking, MD simulations, DFT, ADMET, and toxicity studies.
- Source :
-
Computational biology and chemistry [Comput Biol Chem] 2023 Dec; Vol. 107, pp. 107958. Date of Electronic Publication: 2023 Sep 11. - Publication Year :
- 2023
-
Abstract
- Novel thiazolidine-2,4-dione derivatives, 11a-g, were designed, and synthesized targeting the VEGFR-2 protein. The in vitro studies indicated the abilities of the synthesized derivatives to inhibit VEGFR-2 and prevent the growth of two different cancer cell types, HepG2 and MCF-7. Compound 11 f exhibited the strongest anti-VEGFR-2 activity (IC <subscript>50</subscript> = 0.053 µM). As well, compound 11 f showed impressive anti-proliferative activity against the mentioned cancer cell lines with IC <subscript>50</subscript> values of 0.64 ± 0.01 and 0.53 ± 0.04 µM, respectively. Additionally, compound 11 f arrested the MCF-7 cell cycle at the S phase and increased the overall apoptosis percentage. Furthermore, cell migration assay revealed that compound 11 f has a significant ability to prevent migration and healing potentialities of MCF-7. Moreover, computational studies were used to conduct the molecular investigation of the VEGFR-2-11 f complex. The kinetic and structural features of the complex were examined using molecular dynamics simulations and molecular docking. Besides, Principal component analysis (PCA) was used to explain the dynamics of the VEGFR-2-11 f complex at various spatial scales. The DFT calculations also provided further clarity regarding compound 11 f's structural and electronic features. To evaluate how closely the developed compounds might look like drugs, ADMET and toxicity experiments were computed. To conclude, the presented study demonstrates the potential of compound 11 f as a viable anti-cancer drug, which can serve as a prototype for future structural modifications and further biological investigations.<br />Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. The authors declare the following financial interests/personal relationships which may be considered as potential competing interests.<br /> (Copyright © 2023 Elsevier Ltd. All rights reserved.)
- Subjects :
- Apoptosis
Cell Proliferation
Drug Design
Drug Screening Assays, Antitumor
Molecular Docking Simulation
Molecular Structure
Phosphorylation
Protein Kinase Inhibitors
Structure-Activity Relationship
Thiazolidines pharmacology
Antineoplastic Agents pharmacology
Vascular Endothelial Growth Factor Receptor-2 antagonists & inhibitors
Subjects
Details
- Language :
- English
- ISSN :
- 1476-928X
- Volume :
- 107
- Database :
- MEDLINE
- Journal :
- Computational biology and chemistry
- Publication Type :
- Academic Journal
- Accession number :
- 37714080
- Full Text :
- https://doi.org/10.1016/j.compbiolchem.2023.107958